BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 10084150)

  • 21. Oncogene amplification in neoplastic development and progression of human cancers.
    Schwab M
    Crit Rev Oncog; 1990; 2(1):35-51. PubMed ID: 2091749
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Growth regulation of human neuroblastoma.
    el-Badry OM; Israel MA
    Cancer Treat Res; 1992; 63():105-28. PubMed ID: 1363353
    [No Abstract]   [Full Text] [Related]  

  • 23. The genetic tumor background is an important determinant for heterogeneous MYCN-amplified neuroblastoma.
    Bogen D; Brunner C; Walder D; Ziegler A; Abbasi R; Ladenstein RL; Noguera R; Martinsson T; Amann G; Schilling FH; Ussowicz M; Benesch M; Ambros PF; Ambros IM
    Int J Cancer; 2016 Jul; 139(1):153-63. PubMed ID: 26910568
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Similar chromosomal patterns and lack of N-myc gene amplification in localized and IV-S stage neuroblastomas in infants.
    Hayashi Y; Inaba T; Hanada R; Yamada M; Nakagome Y; Yamamoto K
    Med Pediatr Oncol; 1989; 17(2):111-5. PubMed ID: 2704332
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The MYCN oncogene and differentiation in neuroblastoma.
    Westermark UK; Wilhelm M; Frenzel A; Henriksson MA
    Semin Cancer Biol; 2011 Oct; 21(4):256-66. PubMed ID: 21849159
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma.
    Spitz R; Hero B; Ernestus K; Berthold F
    Med Pediatr Oncol; 2003 Jul; 41(1):30-5. PubMed ID: 12764740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Tumor cytogenetics and prognosis in neuroblastoma].
    Christiansen H; Lampert F
    Monatsschr Kinderheilkd; 1989 Oct; 137(10):666-71. PubMed ID: 2586532
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Telomerase activation by genomic rearrangements in high-risk neuroblastoma.
    Peifer M; Hertwig F; Roels F; Dreidax D; Gartlgruber M; Menon R; Krämer A; Roncaioli JL; Sand F; Heuckmann JM; Ikram F; Schmidt R; Ackermann S; Engesser A; Kahlert Y; Vogel W; Altmüller J; Nürnberg P; Thierry-Mieg J; Thierry-Mieg D; Mariappan A; Heynck S; Mariotti E; Henrich KO; Gloeckner C; Bosco G; Leuschner I; Schweiger MR; Savelyeva L; Watkins SC; Shao C; Bell E; Höfer T; Achter V; Lang U; Theissen J; Volland R; Saadati M; Eggert A; de Wilde B; Berthold F; Peng Z; Zhao C; Shi L; Ortmann M; Büttner R; Perner S; Hero B; Schramm A; Schulte JH; Herrmann C; O'Sullivan RJ; Westermann F; Thomas RK; Fischer M
    Nature; 2015 Oct; 526(7575):700-4. PubMed ID: 26466568
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Coamplification of DDX1 correlates with an improved survival probability in children with MYCN-amplified human neuroblastoma.
    Weber A; Imisch P; Bergmann E; Christiansen H
    J Clin Oncol; 2004 Jul; 22(13):2681-90. PubMed ID: 15226335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biological characteristics of neuroblastoma with partial deletion in the short arm of chromosome 1.
    Hiyama E; Hiyama K; Ohtsu K; Yamaoka H; Fukuba I; Matsuura Y; Yokoyama T
    Med Pediatr Oncol; 2001 Jan; 36(1):67-74. PubMed ID: 11464909
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The 1p deletion is not a reliable marker for the prognosis of patients with neuroblastoma.
    Gehring M; Berthold F; Edler L; Schwab M; Amler LC
    Cancer Res; 1995 Nov; 55(22):5366-9. PubMed ID: 7585602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of amplicons in neuroblastoma: high-resolution mapping using DNA microarrays, relationship with outcome, and identification of overexpressed genes.
    Fix A; Lucchesi C; Ribeiro A; Lequin D; Pierron G; Schleiermacher G; Delattre O; Janoueix-Lerosey I
    Genes Chromosomes Cancer; 2008 Oct; 47(10):819-34. PubMed ID: 18553563
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children.
    Tonini GP; Boni L; Pession A; Rogers D; Iolascon A; Basso G; Cordero di Montezemolo L; Casale F; Pession A; Perri P; Mazzocco K; Scaruffi P; Lo Cunsolo C; Marchese N; Milanaccio C; Conte M; Bruzzi P; De Bernardi B
    J Clin Oncol; 1997 Jan; 15(1):85-93. PubMed ID: 8996128
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Caspase-9 and Apaf-1 are expressed and functionally active in human neuroblastoma tumor cell lines with 1p36 LOH and amplified MYCN.
    Teitz T; Wei T; Liu D; Valentine V; Valentine M; Grenet J; Lahti JM; Kidd VJ
    Oncogene; 2002 Mar; 21(12):1848-58. PubMed ID: 11896617
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project.
    Thompson D; Vo KT; London WB; Fischer M; Ambros PF; Nakagawara A; Brodeur GM; Matthay KK; DuBois SG
    Cancer; 2016 Mar; 122(6):935-45. PubMed ID: 26709890
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data.
    Łastowska M; Viprey V; Santibanez-Koref M; Wappler I; Peters H; Cullinane C; Roberts P; Hall AG; Tweddle DA; Pearson AD; Lewis I; Burchill SA; Jackson MS
    Oncogene; 2007 Nov; 26(53):7432-44. PubMed ID: 17533364
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapid and accurate determination of MYCN copy number and 1p deletion in neuroblastoma by quantitative PCR.
    Anderson J; Gibson S; Williamson D; Rampling D; Austin C; Shipley J; Sebire N; Brock P
    Pediatr Blood Cancer; 2006 Jun; 46(7):820-4. PubMed ID: 16220551
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amplified MYCN in human neuroblastoma: paradigm for the translation of molecular genetics to clinical oncology.
    Schwab M
    Ann N Y Acad Sci; 2002 Jun; 963():63-73. PubMed ID: 12095930
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loss of chromosome 1p may have a prognostic value in localised neuroblastoma: results of the French NBL 90 Study. Neuroblastoma Study Group of the Société Française d'Oncologie Pédiatrique (SFOP).
    Rubie H; Delattre O; Hartmann O; Combaret V; Michon J; Bénard J; Peyroulet MC; Plantaz D; Coze C; Chastagner P; Baranzelli MC; Frappaz D; Lemerle J; Sommelet D
    Eur J Cancer; 1997 Oct; 33(12):1917-22. PubMed ID: 9516824
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An integrated 5-Mb physical, genetic, and radiation hybrid map of a 1p36.1 region implicated in neuroblastoma pathogenesis.
    Spieker N; Beitsma M; van Sluis P; Roobeek I; den Dunnen JT; Speleman F; Caron H; Versteeg R
    Genes Chromosomes Cancer; 2000 Feb; 27(2):143-52. PubMed ID: 10612802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.